Document is current

Article History

First Online: 6 May 2026

Competing interests

: C.E.T. has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N Diagnostics, Celgene, Cognition Therapeutics, Danaher, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Merck, Muna, Nitrase Therapeutics, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Sysmex, Toyama, Vaccinex and Vivoryon. She is editor-in-chief of Alzheimer Research and Therapy , and serves on the editorial boards of Molecular Neurodegeneration , Alzheimer’s & Dementia , Neurology: Neuroimmunology & Neuroinflammation , Medidact Neurologie/Springer , and serves on committees to define guidelines for cognitive disturbances and acute neurology in the Netherlands. She has consultancy/speaker contracts for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Danaher, Eisai, Eli Lilly, Janssen, Merck, Neurogen Biomarking, Nordic Biosciences, Novo Nordisk, Novartis, Olink, Quanterix, Roche, Sanofi and Veravas. A.C.vH.’s research is supported by Stichting Alzheimer Nederland (WE.06‐2021‐06) and the ADDF. A.C.vH is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy, and of AlzTest/Trinitas Dx, a PPS grant from Health Holland. She received consultancy fees (paid to her institution) from Eli Lilly in 2024.